دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 30,000,000 تومان- قیمت ویژه : 6,250,000تومان
دسترسی یکماهه به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 31 ﺭﻭﺯ
قیمت : 3,000,000 تومان- قیمت ویژه : 1,250,000تومان
Closing the deal: a G20 panel report on financing for pandemic threats
Lessons from CONCORD and VENUSCANCER: closing global gaps in cancer care for women
Treatment of MSSA bacteraemia: a call for a personalised approach
The dawn of immunotherapy in mismatch repair proficient colorectal cancer
Translational social medicine for global health: introducing Cases in Global Social Medicine
Global health aid cuts: WHO urges urgent action to protect vulnerable populations
Georges C Benjamin: resolute defender of public health in the USA
Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan
Aligning SPIRIT and SAGER guidelines for equity in clinical trials
Aligning SPIRIT and SAGER guidelines for equity in clinical trials – Authors’ reply
Urodynamic testing in refractory overactive bladder symptoms: the FUTURE study — Manuela Tutolo et al.
Urodynamic testing in refractory overactive bladder symptoms: the FUTURE study — Maurizio Serati et al.
Urodynamic testing in refractory overactive bladder symptoms: the FUTURE study — Thomas M Kessler et al.
Urodynamic testing in refractory overactive bladder symptoms: the FUTURE study – Authors’ reply
Global variation in patterns of care and time to initial treatment for breast, cervical, and ovarian cancer from 2015 to 2018 (VENUSCANCER): a secondary analysis of individual records for 275 792 women from 103 population-based cancer registries in 39 countries and territories
Cloxacillin versus cefazolin for meticillin-susceptible Staphylococcus aureus bacteraemia (CloCeBa): a prospective, open-label, multicentre, non-inferiority, randomised clinical trial
Zanzalintinib plus atezolizumab versus regorafenib in refractory colorectal cancer (STELLAR-303): a randomised, open-label, phase 3 trial
